ArticlePloS one2013
Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 43 citations in OpenAlex.
- DBSCAN and DBCV application to open medical records heterogeneous data for identifying clinically significant clusters of patients with neuroblastoma.BioData mining · 2025Article
- Predicting MYCN amplification in paediatric neuroblastoma: development and validation of a 18F-FDG PET/CT-based radiomics signature.Insights into imaging · 2023Article
- Single-cell next-generation sequencing of circulating tumor cells in patients with neuroblastoma.Cancer science · 2023Article
- MYCN amplification plus 1p36 loss of heterozygosity predicts ultra high risk in bone marrow metastatic neuroblastoma.Cancer medicine · 2022Article
- Bioinformatics analysis of recurrent deletion regions in neuroblastoma.Medical oncology (Northwood, London, England) · 2022Article
- Impact of 11q Loss of Heterozygosity Status on the Response of High-Risk Neuroblastoma With MYCN Amplification to Neoadjuvant Chemotherapy.Frontiers in pediatrics · 2022Article
- Prediction of MYCN Amplification, 1p and 11q Aberrations in Pediatric NeuroblastomaFrontiers in medicine · 2022Article
- Article
- Article
- DEVOLUTION-A method for phylogenetic reconstruction of aneuploid cancers based on multiregional genotyping data.Communications biology · 2021Article
- Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing.European journal of pediatrics · 2021Article
- Distribution of segmental chromosomal alterations in neuroblastoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021Article
- Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line.Journal of experimental & clinical cancer research : CR · 2020Article
- Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.European journal of cancer (Oxford, England : 1990) · 2020Article
- Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.Cancer communications (London, England) · 2019Article
- Investigation of major genetic alterations in neuroblastoma.Molecular biology reports · 2018Article
- Article
- Heterogeneous MYCN amplification in neuroblastoma: a SIOP Europe Neuroblastoma Study.British journal of cancer · 2018Article
- Impact of Disseminated Neuroblastoma Cells on the Identification of the Relapse-Seeding Clone.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017Article
- 11q deletion in neuroblastoma: a review of biological and clinical implications.Molecular cancer · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimGenetic analysis in neuroblastoma has identified the profound influence of MYCN amplification and 11q deletion in patients' prognosis. These two features of high-risk neuroblastoma usually occur as mutually exclusive genetic markers, although in rare cases both are present in the same tumor. The purpose of this study was to characterize the genetic profile of these uncommon neuroblastomas harboring both these high-risk features.
methodsWe selected 18 neuroblastomas with MNA plus 11q loss detected by FISH. Chromosomal aberrations were analyzed using Multiplex Ligation-dependent Probe Amplification and Single Nucleotide Polymorphism array techniques. RESULTS AND
conclusionThis group of tumors has approximately the same high frequency of aberrations as found earlier for 11q deleted tumors. In some cases, DNA instability generates genetic heterogeneity, and must be taken into account in routine genetic diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.